ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

4CMenB vaccine

Also written as “rLP2086”, “rMenB+OMV NZ” and “Meningococcal B vaccine”.

In GlaxoSmithKline’s pipeline, Recombinant protein and outer membrance vesicle vaccine. Its studies are mostly in Meningococcal Infections · Meningitis, Meningococcal · Meningitis · Anemia, Sickle Cell, led by 4 companies.

Drug page4CMenB vaccine: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 2, 200831 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis130 open or runningphase 3since Apr 2, 2008Feb 27, 2006none ahead
Pfizerits history only90 open or runningphase 4since May 14, 2021Oct 11, 2006none ahead
GlaxoSmithKlineits history only71 open or runningphase 4since Feb 6, 2018Feb 14, 2014none ahead
Sanofiits history only20 open or runningphase 3since Sep 4, 2019Sep 4, 2019none ahead
  • Named in GlaxoSmithKline’s own pipeline as Men B vaccine GSK3536829, phase 3, as of Sep 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 27, 2006First study: phase 2 study in Meningococcal InfectionsFirst studyNCT00297817 · 203 enrolled · United States
  2. Apr 2, 20082 phase 3 studiesNCT00657709, NCT00661713
  3. Jul 22, 2008Phase 2 study in Meningococcal InfectionsNCT00721396 · 1,885 enrolled · Belgium, Czech Republic, Germany and more
  4. Jun 29, 2009Phase 2 study in Meningitis, MeningococcalNCT00937521 · 1,507 enrolled · Argentina, Chile, Czech Republic and more
  5. Jul 21, 2009Phase 3 study in Meningococcal InfectionsNCT00944034 · 1,588 enrolled · Belgium, Czechia, Germany and more
  6. Dec 4, 2009Phase 2 study in Meningococcal InfectionsNCT01026974 · 120 enrolled · United Kingdom
  7. Jun 4, 2010Phase 3 study in Meningococcal InfectionsNCT01139021 · 508 enrolled · Czech Republic, Finland
  8. Sep 30, 2010Phase 3 study in N. Meningitidis CarriageNCT01214850 · 2,968 enrolled · United Kingdom
  9. Aug 23, 2011Phase 3 study in Meningococcal InfectionsNCT01423084 · 344 enrolled · Australia, Canada
  10. Oct 18, 2012Phase 3 study in Meningococcal InfectionsNCT01717638 · 805 enrolled · Czech Republic, Italy, Spain and more
  11. Jul 26, 2013Phase 3 study in Meningococcal InfectionsNCT01911221 · 13 enrolled · Germany
  12. Nov 20, 2014Phase 3 study in Meningitis, MeningococcalNCT02305446 · 55 enrolled · Poland

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Recombinant protein and outer membrance vesicle vaccine”the company's pipeline, read by Claude · source
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal gr…”NCIt, read by Claude
“A vaccine containing recombinant bacterial proteins derived from the bacterium Neisseria meningitidis serogroup B, that is used to provide active immunization against and to prevent invasive disease caused by Neisseria meningitidis serogroup B. Upon intramuscular vaccination with meningococcal group”NCIt, by rule

Studies

All 13 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02305446Meningitis, Meningococcal · Poland3CompletedApr 201555
NCT01911221Meningococcal Infections · Germany3CompletedApr 201413
NCT01717638Meningococcal Infections · Czech Republic, Italy, Spain and more3CompletedSep 2013805
NCT01423084Meningococcal Infections · Australia, Canada3CompletedDec 2011344
NCT01214850N. Meningitidis Carriage · United Kingdom3CompletedJan 20122,968
NCT01139021Meningococcal Infections · Czech Republic, Finland3CompletedNov 2010508
NCT01026974Meningococcal Infections · United Kingdom2CompletedSep 2010120
NCT00944034Meningococcal Infections · Belgium, Czechia, Germany and more3CompletedAug 20111,588
NCT00937521Meningitis, Meningococcal · Argentina, Chile, Czech Republic and more2CompletedNov 20101,507
NCT00721396Meningococcal Infections · Belgium, Czech Republic, Germany and more2CompletedJul 20101,885
NCT00661713Meningococcal Infections · Chile3CompletedApr 20101,631
NCT00657709Meningitis, Meningococcal · Austria, Czechia, Finland and more3CompletedJan 20103,630
NCT00297817Meningococcal Infections · United States2CompletedApr 2007203

How it is read

Names in the registry

  • “rLP2086”, 11 entries
  • “rMenB+OMV NZ”, 9 entries
  • “Meningococcal B vaccine”, 6 entries
  • “rMenB+OMV NZ vaccine”, 3 entries
  • “Meningococcal group B vaccine”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.